Drug intelligence / Profile preview

BCL6-II

Development stage: Preclinical
Lead developer: 博仲盛景医药
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

BCL6-II (also known as BCL-5 or BCL6) is a preclinical-stage botanical drug candidate being developed by Botanic Century for the treatment of type II diabetes. It is a single-plant active fraction that acts as a glycosidase inhibitor. Discovered initially in an in vitro assay, BCL6-II has demonstrated the ability to increase glucose tolerance in preclinical models. As a complex mixture of multiple chemical constituents, it is designed to provide a comprehensive therapeutic effect for patients with type II diabetes.

Beyond the preview

Go deeper on BCL6-II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BCL6-II.